Yu ping feng san for pediatric allergic rhinitis
Authors:
Open Access
- 2 April 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (13) , e24534
Abstract
Background: The potential treatment effects and safety of Yu ping feng san (YPFS) for pediatric allergic rhinitis (PAR) patients have yet to be studied systematically. Objectives: To assess the effects and safety of YPFS for treat pediatric patients, allergic rhinitis. Methods: We systematically searched PubMed, EMBASE (Excerpta Medical Database), Cochrane library, Chinese Cochrane Centre's Controlled Trials Register platform, Wanfang Chinese Digital Periodical and Conference Database, China National Knowledge Infrastructure Database, and VIP Chinese Science, from inception dates to November 1, 2019. Randomized controlled trials (RCTs) were included. The risk of bias in the trials was assessed in accordance with the Cochrane Handbook, version 5.1.0. RevMan 5.3 software was used to perform a meta-analysis. Grading of Recommendations Assessment, Development and Evaluation methodology was applied to evaluate the evidence quality for each outcome. The quality of evidence for each outcome measurement was low for 4 outcomes and very low for 5 outcomes. Results: A total of 10 RCTs involving 1069 participants (3–15 years old) fulfilled the inclusion criteria. After exclusion, 8 RCTs were pooled for efficacy assessment. The overall efficacy evaluation result did not show benefit for the experimental group (relative risk 0.32, CI 95% 0.24–0.45; P = .98;) Investigation of variation of serum IgA, immunoglobulin E, IgG in three studies in 2 groups returned no statistical significance. YPFS gave relatively better safety (relative risk 0.29, CI 95% 0.14–0.58; P = .0005; Fig. S8, http://links.lww.com/MD/F751) and lower recurrence rates than did Western medical therapy. Conclusions: Current evidence cannot support the routine use of YPFS for treatment of PAR. This may be due to poor-quality study-design limitations of the included YPFS studies. Our data showed that the use of YPFS for PAR is relatively safe compared to Western medical therapy, but a conclusion could not be drawn because only 5 studies were analyzed. Every study suffered from some methodological limitation. Therefore, further large, rigorously-designed studies are necessary to determine conclusively the utility of YPFS in PAR.Keywords
Funding Information
- National Natural Science Foundation of China (81473523)
- National Science & Technology Pillar Program during the Twelfth Five-year Plan Period of China (2015BAI04B00)
This publication has 15 references indexed in Scilit:
- Clinical Practice GuidelineOtolaryngology–Head and Neck Surgery, 2015
- Screening Active Components from Yu-Ping-Feng-San for Regulating Initiative Key Factors in Allergic SensitizationPLOS ONE, 2014
- Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Regulates the Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 and the Activity of Intestinal Alkaline Phosphatase in CulturesPLOS ONE, 2014
- Prevalence of Allergic Rhinitis in ChinaAllergy, Asthma & Immunology Research, 2014
- Immunological mechanisms of allergen-specific immunotherapyAllergy, 2011
- Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodiesJournal of Allergy and Clinical Immunology, 2011
- Rhinitis and sinusitisJournal of Allergy and Clinical Immunology, 2010
- Rhinitis: A Practical and Comprehensive Approach to Assessment and TherapyThe Journal of Otolaryngology, 2007
- IgE-Mediated Allergen Presentation and Blocking Antibodies: Regulation of T-Cell Activation in AllergyInternational Archives of Allergy and Immunology, 2006
- Immunomodulatory Effects of a Traditional Chinese Medicine with Potential Antiviral Activity: A Self-Control StudyThe American Journal of Chinese Medicine, 2006